Aaron T. Chin

Aaron T. Chin

Auto-generated profile, based on publicly available information

Aaron T. Chin

UCLA Health Information Technology, UCLA Health, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
AJArman Jahangiri
Arman Jahangiri
ACAaron T. Chin
Aaron T. Chin
PFPatrick M. Flanigan
Patrick M. Flanigan
RCRebecca Chen
Rebecca Chen
KBKrystof Bankiewicz
Krystof Bankiewicz
MAManish K. Aghi
Manish K. Aghi
Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor prognosis. Attempts to develop targeted therapies have been hindered because the blood-brain barrier prevents many drugs from reaching tumors cells. Furthermore, systemic toxicity of drugs often limits their therapeutic potential. A number of alternative methods of delivery have been developed, one of which is convection-enhanced delivery (CED), the focus of this review. The authors describe CED as a therapeutic measure and review preclinical studies and the most prominent clinical trials of CED in the treatment of glioblastoma. The utilization of this technique for the delivery of a variety of agents is covered, and its shortcomings and challenges are discussed in detail.

26 November 2025 in NEJM AI
Verified
Journal Article
Closed access
PLPaul J. Lukac
Paul J. Lukac
WTWilliam Turner
William Turner
SVSitaram Vangala
Sitaram Vangala
ACAaron T. Chin
Aaron T. Chin
JKJoshua Khalili
Joshua Khalili
JMJohn N. Mafi
John N. Mafi
Ambient artificial intelligence (AI) scribes record patient encounters and rapidly generate visit notes, representing a promising solution to documentation burden and physician burnout. However, the scribes’ impacts have not been examined in randomized clinical trials. In this parallel three-group pragmatic randomized clinical trial, 238 outpatient physicians, representing 14 specialties, were assigned 1:1:1 via covariate-constrained randomization (balancing on time-in-note, baseline burnout score, and clinic days per week) to either one of two AI scribe applications — Microsoft Dragon Ambient eXperience (DAX) Copilot or Nabla — or a usual-care control group from November 4, 2024, to January 3, 2025. The primary outcome was the change from baseline log writing time-in-note. Secondary end points measured by surveys included the Mini-Z 2.0, a four-item physician task load (PTL), and Professional Fulfillment Index — Work Exhaustion (PFI-WE) scores to evaluate aspects of burnout; work environment; stress; and targeted questions addressing safety, accuracy, and usability. DAX was used in 33.5% of 24,696 visits; Nabla was used in 29.5% of 23,653 visits. Nabla users experienced a 9.5% (95% confidence interval [CI], −17.2% to −1.8%; P=0.02) decrease in time-in-note versus the control group, whereas DAX users exhibited no significant change versus the control group (−1.7%; 95% CI, −9.4% to +5.9%; P=0.66). Increases in total Mini-Z (scale 10–50; DAX 2.83 [95% CI, +1.28 to +4.37]; Nabla +2.69 [95% CI, +1.14 to +4.23]) and reductions in PTL (scale 0–400; DAX −39.9 [95% CI, −71.9 to −7.9]; Nabla −31.7 [95% CI, −63.8 to +0.4]), and PFI-WE (scale 0–4; DAX 0.32 [95% CI,−0.55 to −0.08]; Nabla −0.23 [95% CI, −0.46 to +0.01]) scores suggest improvement for users of either scribe versus the control. One grade 1 (mild) adverse event was reported, while clinically significant inaccuracies were noted “occasionally” on five-point Likert questions (DAX 2.7 [95% CI, 2.4 to 3.0]; Nabla 2.8 [95% CI, 2.6 to 3.0]). Nabla reduced time-in-note versus the control. Both DAX and Nabla resulted in potential improvements in burnout, task load, and work exhaustion, but these secondary end point findings need confirmation in larger, multicenter trials. Clinicians reported that performance was similar across the two distinct platforms, and occasional inaccuracies observed in either scribe require ongoing vigilance. (Funded by the University of California, Los Angeles, Department of Medicine and others; ClinicalTrials.gov number, NCT06792890.)

1 February 2015 in Neurosurgery
Verified
Journal Article
Closed access
AJArman Jahangiri
Arman Jahangiri
ACAaron T. Chin
Aaron T. Chin
JWJeffrey R. Wagner
Jeffrey R. Wagner
SKSandeep Kunwar
Sandeep Kunwar
CAChristopher Ames
Christopher Ames
MAManish K. Aghi
Manish K. Aghi
To 2013. RESULTS: Fifty patients (56% male) with median age of 59 years (range, 8-76) were newly diagnosed with clival chordoma of mean diameter 3.3 cm (range, 1.5-6.7). Symptoms included headaches (38%), diplopia (36%), and dysphagia (14%). Procedures included transsphenoidal (n = 34), transoral (n = 4), craniotomy (n = 5), and staged approaches (n = 7). Gross total resection (GTR) rate was 52%, with 83% mean volumetric reduction, values that improved over time. While the lower third of the clivus was the least likely superoinferior zone to contain tumor (upper third = 72%/middle third = 82%/lower third = 42%), it most frequently contained residual tumor (upper third = 33%/middle third = 38%/lower third = 63%; P < .05). Symptom improvement rates were 61% (diplopia) and 53% (headache). Postoperative radiation included proton beam (n = 19), cyberknife (n = 7), intensity-modulated radiation therapy (n = 6), external beam (n = 10), and none (n = 4). At last follow-up of 47 patients, 23 (49%) remain disease-free or have stable residual tumor. Lower third of clivus progressed most after GTR (upper/mid/lower third = 32%/41%/75%). In a multivariate Cox proportional hazards model, male gender (hazard ratio [HR] = 1.2/P = .03), subtotal resection (HR = 5.0/P = .02), and the preoperative presence of tumor in the middle third (HR = 1.2/P = .02) and lower third (HR = 1.8/P = .02) of the clivus increased further growth or regrowth, while radiation modality did not. CONCLUSION: Our findings underscore long-standing support for GTR as reducing chordoma recurrence. The lower third of the clivus frequently harbored residual or recurrent tumor, despite staged approaches providing mediolateral (transcranial + endonasal) or superoinferior (endonasal + transoral) breadth. There was no benefit of proton-based over photon-based radiation, contradicting conventional presumptions. ABBREVIATIONS: GTR, gross total resection IMRT, intensity-modulated radiation therapy STR, subtotal resection UCSF, University of California, San Francisco...

1 February 2019 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
ACA. T. Chin
A. T. Chin
JRJamie Rylance
Jamie Rylance
SMS. Makumbirofa
S. Makumbirofa
SMS. Meffert
S. Meffert
TVT. Vu
T. Vu
JMJ. Metcalfe
J. Metcalfe
OBJECTIVE: To examine the prevalence and magnitude of chronic lung disease (CLD) and its association with empiric anti-tuberculosis treatment (due to lack of bacteriologic confirmation) among recurrent tuberculosis (TB) survivors in a human immunodeficiency virus (HIV) prevalent setting. METHODS: Prospective cohort study of retreatment TB survivors in Harare, Zimbabwe. At median follow-up of 2 years post-treatment initiation, we characterized mortality, respiratory impairment, and mental health. RESULTS: Among 175 retreatment TB survivors, 65% of whom were HIV-positive and 21% had been empirically treated, multiparameter CLD was noted at follow-up among 14% of patients (95%CI 9.0–19.7), with a six-fold increase in age-adjusted death in the first year following treatment completion. Empirically treated TB (relative risk [RR] 3.4, 95%CI 1.4–8.3) was associated with CLD, as was the number of previous anti-tuberculosis treatment courses in dose-dependent fashion (three vs. one, RR 6.2, 95%CI 1.7–22.1). Among retreatment TB survivors, 33% (95%CI 26.0–40.1) had persistent respiratory symptoms (Chronic Obstructive Pulmonary Disease Assessment Test score 10); 26% (95%CI 19.8–33.0) significant deficits in exercise capacity (median incremental shuttle walk test distance, 550 m; Q1–Q3 440–730 m); 83% (95%CI 75.7–89.7) residual radiographic abnormalities on chest X-ray; 12% (95%CI 6.6–16.1%) moderate-to-severe obstruction on spirometry; and 13% (95%CI 7.6–17.5%) major depression. CONCLUSIONS: Despite successful treatment, retreatment TB survivors retain a substantial risk of morbidity and mortality.

1 May 2015 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
AJArman Jahangiri
Arman Jahangiri
JWJeffrey R. Wagner
Jeffrey R. Wagner
ACAaron T. Chin
Aaron T. Chin
SHSung Won Han
Sung Won Han
MTMai T. Tran
Mai T. Tran
MAManish K. Aghi
Manish K. Aghi

18 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RGRoy Gerona
Roy Gerona
AWAnita Wen
Anita Wen
ACAaron T. Chin
Aaron T. Chin
CKCatherine A. Koss
Catherine A. Koss
PBPeter Bacchetti
Peter Bacchetti
MGMonica Gandhi
Monica Gandhi
Tuberculosis (TB) is the leading cause of death from an infectious pathogen worldwide and the most prevalent opportunistic infection in people living with HIV. Isoniazid preventive therapy (IPT) reduces the incidence of active TB and reduces morbidity and mortality in HIV-infected patients independently of antiretroviral therapy. However, treatment of latent or active TB is lengthy and inter-patient variability in pharmacokinetics and adherence common. Current methods of assessing adherence to TB treatment using drug levels in plasma or urine assess short-term exposure and pose logistical challenges. Drug concentrations in hair assess long-term exposure and have demonstrated pharmacodynamic relevance in HIV. A large hair sample from a patient with active TB was obtained for assay development. Methods to pulverize hair and extract isoniazid were optimized and then the drug detected by liquid chromatography/ tandem mass spectrometry (LC/MS-MS). The method was validated for specificity, accuracy, precision, recovery, linearity and stability to establish the assay’s suitability for therapeutic drug monitoring (TDM). Hair samples from patients on directly-observe isoniazid-based latent or active TB therapy from the San Francisco Department of Public Health TB clinic were then tested. Our LC/MS-MS-based assay detected isoniazid in quantities as low as 0.02ng/mg using 10–25 strands hair. Concentrations in spiked samples demonstrated linearity from 0.05–50ng/mg. Assay precision and accuracy for spiked quality-control samples were high, with an overall recovery rate of 79.5%. In 18 patients with latent or active TB on treatment, isoniazid was detected across a wide linear dynamic range. An LC-MS/MS-based assay to quantify isoniazid levels in hair with performance characteristics suitable for TDM was developed and validated. Hair concentrations of isoniazid assess long-term exposure and may be useful for monitoring adherence to latent or active TB treatment in the setting of HIV.